Robert G. Gish, MD, FAASLD, AGAF, FAST
Principal, Robert G. Gish Consultants, LLC
La Jolla, California
Adjunct Professor of Medicine, University of Nevada, Reno
and University of Nevada, Las Vegas
Medical Director, Hepatitis B Foundation
Adjunct Professor, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
This enduring activity is a faculty-led didactic and case-based lecture focusing on the management of patients with hepatocellular carcinoma (HCC).
This activity is intended for U.S.-based hematologists/oncologists, hepatologists, gastroenterologists, interventional radiologists, pathologists, and other members of the multidisciplinary oncology team (NPs, PAs, pharmacists) responsible for the care of patients with HCC.
Upon completion of the program, attendees should be able to:
- Evaluate evidence from clinical trials assessing emerging therapies for the treatment of patients with advanced HCC
- Devise strategies to manage the therapy-related AEs associated with guideline-recommended systemic therapies for the treatment of advanced HCC
- Interpret data on biomarkers that may help inform treatment decision making for patients with advanced HCC
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the management of patients with HCC.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Robert G. Gish, MD, FAASLD, AGAF, FAST reports the following disclosures:
|Consultant and/or Advisory (in the last 2 years)||Abbott, AbbVie, Altimunne, Antios, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Merck, Pfizer, Venatorx|
|Scientific or Clinical Advisory Board||AbbVie, Antios, Eiger, Enyo, Gilead, HepQuant, Intercept, Janssen, Merck, Prodigy|
|Current Clinical Trial Alliance||Topography Healthy|
|Chair Clinical Advisory Board||Prodigy|
|Advisory Consultants: Diagnostic Companies||Fibronostics, Fujifilm/Wako, Perspectum, Quest, Sonic Incytes|
|Speakers Bureau||AbbVie, BMS, Eisai, Genentech, Gilead Sciences Inc., Intercept|
|Data Safety Monitoring Board||Arrowhead, CymaBay Therapeutics, Durect|
|Consulting Confidentiality Agreements||AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals Inc., Arrowhead, Arterys Inc, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Assoc., CymaBay Therapeutics Inc., DiaSorin Inc., Dova Pharmaceuticals, DRG Abacus, DURECT Corporation, Dynavax, Echosens, Eiger, Eisai, Enyo, Exelixis, Fibronostics Inc., Forty-Seven Inc., Fujifilm Wako Diagnostics, Gilead, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen/J&J, KannaLife, Kezar Life Sciences Inc., Laboratory for Advanced Medicine, Labyrinth Holdings, Life Line Screening, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Perspectum, Pfizer, Pharmaceutical Research Associates, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Sagimet Inc., Salix, Saol Bermuda Ltd., Shenzhen HEC Industrial Development, Shionogi Inc., Spring Bank, Tonghua Anrate Biopharmaceutical, Topography Health, Trimaran, Venatorx, Viravaxx AG|
|Minor stock shareholder (liver space noted only)||RiboSciences, CoCrystal|
|Stock Options||Eiger, Genlantis, HepQuant, AngioCrine|
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Deb Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to the Med Learning Group.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.